(Reuters) -Drug developer Arvinas said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer to a third party.

Shares of Arvinas were down 3.4% in extended trading.

The drug vepdegestrant is currently under review by the U.S. Food and Drug Administration for a type of breast cancer, and the regulator will give its potential approval decision in June.

Arvinas said it will limit additional expenditures on vepdegestrant to support activities required for making the drug ready for commercialization.

“The companies are aligned in their belief that finding a third-party commercial partner is the best path forward … and ensure vepdegestrant is available promptly if approved for use by regulatory authorities,” said Arvinas.

See Full Page